alexa Tumor Suppressor Gene Alteration As Early Markers In Ulcerative Colitis Associated Carcinoma And Dysplasia
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Clinical & Cellular Immunology
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Zainab Mohammed Taher Jaafar
Accepted Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.019
Abstract
Ulcerative colitis (UC), involves the colon and rectum. Inflammation and ulcers typically affect only the innermost lining in these areas. The etiology of UC is not fully elucidated the causes are likely based on combination of heredity and environmental factors. People who had UC for at least eight years have a higher risk of developing colon cancer. The risk is even greater when inflammation affects the entire colon, approximately 10% of UC develop colorectal neoplastic. In long standing UC, a dysplasia carcinoma sequences is widely accepted, the tumor genesis being considered associated with long term inflammation and oxidative stress causing DNA damage.The early marker of neoplastic progression is mutation in P53 gene is reported to be an early event in UC -associated carcinogenesis, as analyzed with reference to genetic instability, the other marker chromosomal alteration such as chromosome aberration, sister chromatid breaks or exchange and also detected by comparative genomic hybridization and flow cytometry. In this study, the colonic biopsies which collected from patients of UC and colon cancer were examined for gene expression of P53 gene and Bcl-2 gene on the levels of in situ hybridization. The results indicated accumulated mutations in P53 gene in the inflamed colonic biopsies, this give an indication for progression of carcinogenesis. While on the level on Bcl-2 gene, the results showed increasing in the activity of the gene, resulting in increase in gene expressing which is similar in gene expression in tissues of colon cancer biopsies. The extent of p53 gene was 33.3 in high grade, 63.93 in moderate grade and 2.77 in low grade. The extent of Bcl-2 was 75.03 in high grade, 24.97 in moderate grade in tissue of colon cancer while the intensity of P53 was 36.1in low grade, 55.6 in moderate grade and 8.3 in high grade, and the intensity of Bcl-2 was 41.63 in high grade, 55.53 in moderate grade and 2.76 in low grade in colon cancer tissues. The extent of P53 was 63.97 in high grade, 27.73 in moderate grade, 8.3 in low grade in UC tissues, while in Bcl-2 was 66.3 in high grade, 25 in moderate grade and 8.37 in low grade in UC tissues. The intensity of P53 was 18.47 in high grade, 47.2 in low grade and 33.3 in high grade in UC tissues and the intensity of Bcl-2 was 7.86 in high grade, 50.87 in moderate grade and 21.27 in low grade of UC tissues. In addition to some immunological tests to insight into the disturbance associated with clinical expression of UC. It was noticed that the immunoglobulins that include IgG, IgA, IgM, as well as some complements such as C3, C4 were increased in both UC and Colon cancer in the sera of the patients. Conclusion: The detection of P53 gene and Bcl-2 gene in chronic UC and colon cancer give early detection for diagnostic and therapeutic and monitoring purposes.
Biography
Zainab Mohammed Taher Jaafar did his PhD in Biology and works in Ministry of Science and Technology, Head Department in the Biotechnology Center. He is interested in immunology field, especially in autoimmune diseases. He has more than 35 published articles in biological fields.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

agriaquaculture@omicsonline.com

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

biochemjournals@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

chemistryjournals@omicsonline.com

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

clinicaljournals@omicsonline.com

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

engineeringjournals@omicsonline.com

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

nutritionjournals@omicsonline.com

1-702-714-7001Extn: 9042

General Science

Andrea Jason

generalscience@omicsonline.com

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

geneticsmolbio@omicsonline.com

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immunomicrobiol@omicsonline.com

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

nursinghealthcare@omicsonline.com

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

medicaljournals@omicsonline.com

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuropsychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

pharmajournals@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords